Trius Therapeutics, Inc.
http://www.triusrx.com/index.php
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Trius Therapeutics, Inc.
Sangamo Can Take Lead In Fabry Gene Therapy
Avrobio dropping out of the race means Sangamo can take advantage but its gene therapy must show long-term efficacy in patients not receiving enzyme replacement therapy.
Keeping Track: Idorsia’s Quviviq Is FDA’s First Novel Approval Of 2022; AbbVie’s Rinvoq Gains Eczema Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Idorsia Adds Hollywood Sparkle To Sleep Drug Quviviq
The Swiss biotech needs to wait for a scheduling review before it can officially launch the insomnia drug Quviviq but this delay gives Idorsia a few months to prime the US market with educational campaigns.
Idorsia Advances Lupus Drug Into Phase III Despite Mid-Stage Fail
The Swiss biotech is confident its S1P1 receptor modulator can be an effective treatment for lupus but the move into late-stage studies has raised some eyebrows.